Gilead Sciences Inc (GILD)

82.00
0.29 0.35
NASDAQ : Health Care
Prev Close 82.29
Open 82.36
Day Low/High 81.84 / 82.90
52 Wk Low/High 77.92 / 120.37
Volume 3.34M
Avg Volume 9.34M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 108.35B
EPS 10.10
P/E Ratio 9.01
Div & Yield 2.08 (2.50%)

Latest News

Upgrade Confirms Gilead's Price Strength

Upgrade Confirms Gilead's Price Strength

But is it too late?

Upgrade Confirms Gilead's Price Strength

Upgrade Confirms Gilead's Price Strength

But is it too late?

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AUDC, AVNW, CONN, GILD, HTLD, MCFT, TICC Downgrades: AOBC, CG, FRGI, GS, GWB, HOV, JW.A, JW.B, KNL, LDOS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Monday, September 11

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Monday, September 11

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer

Cramer explains why the rebuilding of Houston will be faster than the rebuilding of New Orleans after Katrina and considers how a Micron Tech breakout would be a win for technology stocks.

Getting Bullish on Gilead

Getting Bullish on Gilead

I'm setting up a risk reversal to either buy the stock lower or participate in the upside.

Gilead Sciences To Present At Citi's 12th Annual Biotech Conference On Wednesday, September 6

Gilead Sciences To Present At Citi's 12th Annual Biotech Conference On Wednesday, September 6

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Gilead's Chief Operating Officer, Norbert W.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

How A Girl from India Came to Rule JPM's North America M&A Group

How A Girl from India Came to Rule JPM's North America M&A Group

Getting M&A insight from JPM's Anu Aiyengar is like winning the lotto.

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

From political signals to the rebuilding and recovery efforts in Texas, Jim Cramer says investors should pay attention to what's supporting stocks.

Gilead Sciences Breaks Out

Gilead Sciences Breaks Out

With stock back up to $80, it's time to adjust the parameters.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Gilead Sciences Breaks Out

Gilead Sciences Breaks Out

With stock back up to $80, it's time to adjust the parameters.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

That would mean that there is the chance for a comeback here of some note.

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Here's what you need to know now for Tuesday, August 29.

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics stock was upgraded at Wedbush as Gilead's proposed deal for Kite Pharma raises awareness of Juno's treatments.

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Jim Cramer says people care about natural disasters, but the markets are moved by data points, such as Apple's iPhone news.

Bears Still Can't Execute in the 'Red Zone'

Bears Still Can't Execute in the 'Red Zone'

Monday's action failed to change the overall character of the market

Stocks Close Mixed as Wall Street Struggles With Houston's Harvey Disaster

Stocks Close Mixed as Wall Street Struggles With Houston's Harvey Disaster

Stocks finished Monday mixed.

FDA Approves Abbott Heart Device, Stock Rises

FDA Approves Abbott Heart Device, Stock Rises

The HeartMate 3 received regulatory approval.

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

This market is focused on Apple and Gilead's planned acquisition of Kite.

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Gilead is acquiring Kite Pharma.

TheStreet Quant Rating: B (Buy)